Cinta Hierro

2.0k total citations · 1 hit paper
70 papers, 1.3k citations indexed

About

Cinta Hierro is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Cinta Hierro has authored 70 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 26 papers in Molecular Biology and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Cinta Hierro's work include Cancer Immunotherapy and Biomarkers (19 papers), Fibroblast Growth Factor Research (16 papers) and Lung Cancer Treatments and Mutations (10 papers). Cinta Hierro is often cited by papers focused on Cancer Immunotherapy and Biomarkers (19 papers), Fibroblast Growth Factor Research (16 papers) and Lung Cancer Treatments and Mutations (10 papers). Cinta Hierro collaborates with scholars based in Spain, United States and Switzerland. Cinta Hierro's co-authors include Josep Tabernero, Jordi Rodón, Juan Martín-Liberal, María Ochoa de Olza, Funda Meric‐Bernstam, Rastislav Bahleda, Ben Tran, Lipika Goyal, Milind Javle and Robin Kate Kelley and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Cinta Hierro

67 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

2021 171 citations Funda Meric‐Bernstam, Rastislav Bahleda et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cinta Hierro Spain	19	700	501	460	368	169	70	1.3k
Anastasia G Eleftheraki Greece	20	612 0.9×	357 0.7×	250 0.5×	316 0.9×	107 0.6×	37	1.2k
Wolfgang Eisterer Austria	21	712 1.0×	564 1.1×	373 0.8×	365 1.0×	204 1.2×	95	1.7k
Amy Harlow United States	9	537 0.8×	442 0.9×	255 0.6×	692 1.9×	232 1.4×	10	1.6k
Nabil Adra United States	19	460 0.7×	313 0.6×	757 1.6×	622 1.7×	107 0.6×	119	1.4k
Juan Martín-Liberal Spain	19	1.1k 1.6×	346 0.7×	189 0.4×	431 1.2×	415 2.5×	84	1.6k
Biagio Paolini Italy	20	305 0.4×	325 0.6×	318 0.7×	213 0.6×	97 0.6×	80	1.0k
Damien Pouessel France	20	844 1.2×	377 0.8×	638 1.4×	790 2.1×	54 0.3×	120	1.8k
Andrea Fontana Italy	19	549 0.8×	285 0.6×	153 0.3×	335 0.9×	100 0.6×	50	1.0k
Tyler P. Robin United States	17	608 0.9×	330 0.7×	272 0.6×	405 1.1×	69 0.4×	55	1.3k
Marius Lund‐Iversen Norway	17	499 0.7×	279 0.6×	122 0.3×	523 1.4×	169 1.0×	60	1.0k

Countries citing papers authored by Cinta Hierro

Since Specialization

Citations

This map shows the geographic impact of Cinta Hierro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cinta Hierro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cinta Hierro more than expected).

Fields of papers citing papers by Cinta Hierro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cinta Hierro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cinta Hierro. The network helps show where Cinta Hierro may publish in the future.

Co-authorship network of co-authors of Cinta Hierro

This figure shows the co-authorship network connecting the top 25 collaborators of Cinta Hierro. A scholar is included among the top collaborators of Cinta Hierro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cinta Hierro. Cinta Hierro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hernando, Jorge, Javier Molina‐Cerrillo, Rocio García‐Carbonero, et al.. (2025). Data from Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). DIGITAL.CSIC (Spanish National Research Council (CSIC)).

Hernando, Jorge, Javier Molina‐Cerrillo, Rocio García‐Carbonero, et al.. (2025). Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). Clinical Cancer Research. 31(22). 4655–4663.

May, Anne M., Antoine Adenis, Andreia Capela, et al.. (2025). Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study. European Journal of Cancer. 218. 115278–115278. 1 indexed citations

Pous, Anna, et al.. (2023). HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies. International Journal of Molecular Sciences. 24(14). 11403–11403. 21 indexed citations

Prat, Aleix, Tomás Pascual, Manel Juan, et al.. (2023). 1056P Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI-1904 ACROPOLI). Annals of Oncology. 34. S639–S640. 1 indexed citations

Sun, Chen, et al.. (2022). Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going. Clinical Colorectal Cancer. 21(2). 71–79. 4 indexed citations

Cucurull, Marc, Montse Sánchez‐Céspedes, Cinta Hierro, et al.. (2022). Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies. Frontiers in Oncology. 11. 793121–793121. 21 indexed citations

Meric‐Bernstam, Funda, Rastislav Bahleda, Cinta Hierro, et al.. (2021). Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study. Cancer Discovery. 12(2). 402–415. 171 indexed citations breakdown →

Grande, Enrique, Rocio García‐Carbonero, Àlex Teulé, et al.. (2021). 575TiP Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914). Annals of Oncology. 32. S624–S625. 2 indexed citations

10.

Hierro, Cinta, J.P. Suárez Fernández, Cristina Bugés, et al.. (2020). Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents. Drugs in Context. 9. 1–13. 5 indexed citations

11.

Bahleda, Rastislav, Antoîne Italiano, Cinta Hierro, et al.. (2019). Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clinical Cancer Research. 25(16). 4888–4897. 187 indexed citations

12.

Voss, Martin H., Cinta Hierro, Rebecca S. Heist, et al.. (2019). A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clinical Cancer Research. 25(9). 2699–2707. 102 indexed citations

13.

Bahleda, Rastislav, Funda Meric‐Bernstam, Lipika Goyal, et al.. (2018). Phase I dose-escalation study of TAS-120, a highly selective, covalently bound FGFR inhibitor, in patients with advanced solid tumors. Clinical Trials. 78(13). 1 indexed citations

14.

García-Ruiz, Alonso, Juan Martín-Liberal, Cinta Hierro, et al.. (2018). Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability. Annals of Oncology. 29. viii653–viii653. 5 indexed citations

15.

Tran, Ben, Funda Meric‐Bernstam, Hendrik‐Tobias Arkenau, et al.. (2018). Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s. Annals of Oncology. 29. ix49–ix50. 15 indexed citations

16.

Hierro, Cinta, Javier Torres-Jiménez, Juan Martín-Liberal, et al.. (2017). FGFR 360° resistance: Establishing a translational research framework in FGFR-altered (FGFRalt) patients (pt) treated with fibroblast growth factor receptor inhibitors (FGFRinh). Annals of Oncology. 28. v575–v575.

17.

Hierro, Cinta, et al.. (2017). Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?. Annals of Oncology. 28(6). 1207–1216. 31 indexed citations

18.

Alsina, María, Cinta Hierro, Javier Sastre, et al.. (2016). Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ). Annals of Oncology. 27. vi213–vi213. 1 indexed citations

19.

Taberna, Miren, Antonio Rullan, Cinta Hierro, et al.. (2015). Late toxicity after radical treatment for locally advanced head and neck cancer. Oral Oncology. 51(8). 795–799. 29 indexed citations

20.

Hierro, Cinta, Jordi Rodón, & Josep Tabernero. (2015). Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. Seminars in Oncology. 42(6). 801–819. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact